Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence
Dong‐Hwan Jung, Eunyoung Tak, Shin Hwang, Gi‐Won Song, Chul‐Soo Ahn, Ki‐Hun Kim, Deok‐Bog Moon, Tae‐Yong Ha, Gil‐Chun Park, Baek‐Yeol Ryoo, Kyung Jin Lee, Nayoung Kim, Jae‐Hyeon Kwon, Eun‐Kyoung Jwa, Sung‐Gyu Lee – 30 April 2018 – Both sorafenib and mammalian target of rapamycin inhibitor (mTORi) have antitumor effects. This study aimed to evaluate their antitumor effects in liver transplantation (LT) recipients with hepatocellular carcinoma (HCC) recurrence.